Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UTS2R | Q9UKP6 | 15/20 | 0.52 |
| ▸ | OPRK1 | P41145 | 10/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 7/20 | 0.52 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.37 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3103255 | 0.93 | OPRK1 (0.60) | UTS2ROPRK1CYP3A4CYP2D6ROCK2 | |
| SCHEMBL2953935 | 0.90 | UTS2R (0.55) | UTS2ROPRK1CYP3A4CYP2D6ROCK2 | |
| SCHEMBL3117129 | 0.88 | OPRK1 (0.56) | UTS2ROPRK1CYP3A4CYP2D6 | |
| SCHEMBL3109022 | 0.85 | OPRK1 (0.51) | UTS2ROPRK1CYP3A4CYP2D6 | |
| SCHEMBL2957823 | 0.85 | OPRK1 (0.72) | UTS2ROPRK1CYP3A4CYP2D6 | |
| SCHEMBL2955680 | 0.85 | OPRK1 (0.72) | UTS2ROPRK1CYP3A4CYP2D6 | |
| SCHEMBL2954070 | 0.84 | OPRK1 (0.73) | UTS2ROPRK1CYP3A4CYP2D6ROCK2 | |
| SCHEMBL3094893 | 0.83 | UTS2R (0.48) | UTS2ROPRK1CYP3A4CYP2D6 | |
| SCHEMBL3094749 | 0.83 | UTS2R (0.54) | UTS2ROPRK1CYP3A4CYP2D6 | |
| SCHEMBL2953767 | 0.83 | UTS2R (0.57) | UTS2ROPRK1CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100256130-A1 | MORPHOLINYL AND PYRROLIDINYL ANALOGS | GOODMAN KRISTA B | 2010-10-07 | — | — | US | disclosed |
| US-7749998-B2 | Morpholinyl and pyrrolidinyl analogs | GLAXOSMITHKLINE LLC (US) | 2010-07-06 | — | — | US | disclosed |
| US-20090275571-A1 | MORPHOLINYL AND PYRROLIDINYL ANALOGS | SMITHKLINE BEECHAM CORPORATION | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256130-A1 | MORPHOLINYL AND PYRROLIDINYL ANALOGS | UTS2R, AVPR2, VIPR2 | UTS2R 1/4885OPRK1 207/4885CYP3A4 4049/4885 |
| US-20090275571-A1 | MORPHOLINYL AND PYRROLIDINYL ANALOGS | UTS2R, AVPR2, VIPR2 | UTS2R 1/4885OPRK1 207/4885CYP3A4 4049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.